The development of microbubble contrast agents has broadened the scope of medical
ultrasound imaging. Along with dedicated imaging techniques, these agents provide …

Introduction: Atezolizumab plus bevacizumab therapy is extremely effective in the treatment
of intermediate-stage hepatocellular carcinoma (HCC), with a response rate of 44%, as …

Contrast-enhanced ultrasound (CEUS) is a dependable modality for the diagnosis of various
clinical conditions. A judicious selection of ultrasound contrast agent (UCA) is imperative for …

Background Liver Imaging Reporting and Data System (LI-RADS) was designed for contrast-
enhanced US (CEUS) with pure blood pool agents to diagnose hepatocellularfcarcinoma …

Sonazoid™ versus SonoVue® for Diagnosing Hepatocellular Carcinoma Using Contrast-Enhanced
Ultrasound in At-Risk Individuals: A Prospective, Single-Center, Intraindividual, Noninferiority …

Hepatocellular carcinoma (HCC) is refractory to treatment under the following conditions:(A)
a large number of tumors,(B) large tumor size,(C) vascular invasion or extrahepatic spread …

Purpose The aim of this study was to evaluate the association of contrast-enhanced
ultrasound (CEUS) features using Sonazoid for liver nodules with Liver Imaging Reporting …

Please see the Editorial Comment by Kevin G. King discussing this article. BACKGROUND.
Contrast-enhanced ultrasound (CEUS) LI-RADS version 2017 (v2017) applies only to CEUS …

Hepatocellular carcinoma (HCC) is a unique cancer entity that can be noninvasively
diagnosed using imaging modalities without pathologic confirmation. In 2018, several major …

Objectives To evaluate the diagnostic accuracy of perfluorobutane contrast-enhanced
ultrasonography (CEUS) for hepatocellular carcinoma (HCC) and to explore how accuracy …